Clinical Trials Sponsored by Dupont Merck

Total 5228 results

Merck KGaA, Darmstadt, Germany

Completed

Oral Bioavailability and Mass Balance Trial With Pimasertib

Locally Advanced or Metastatic Solid Tumors

Hungary
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) (DANCHEONG)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) (DISCOVER)

Ocular Hypertension | Open Angle Glaucoma
Merck Sharp & Dohme LLC

Completed

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Glaucoma
Merck Sharp & Dohme LLC

Terminated

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) (STOP)

Breast Neoplasm | Brain Neoplasm | Second Neoplasm
Merck Sharp & Dohme LLC

Terminated

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell
Merck Sharp & Dohme LLC

Completed

Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

Glioma
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Chemotherapy-Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm
Merck Sharp & Dohme LLC

Completed

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Anesthesia
Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)

Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Diabetes Mellitus, Type 2 | End-Stage Kidney Disease
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Spondylitis, Ankylosing
Merck Sharp & Dohme LLC

Completed

Residual Curarization and Its Incidence at Tracheal Extubation (P08194) (RECITE)

Observation of Neuromuscular Block
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

Colorectal Adenoma
Merck Sharp & Dohme LLC

Completed

Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis | Brain Neoplasms
Merck Sharp & Dohme LLC

Completed

A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)

Postoperative Pain
Merck Sharp & Dohme LLC

Completed

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

GARDASIL Reexamination Study (V501-059)

Human Papillomavirus (HPV) Infection
Merck Sharp & Dohme LLC

Completed

ROTATEQ Reexamination Study (V260-037)

Gastroenteritis Rotavirus
Merck Sharp & Dohme LLC

Completed

Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

Gastroenteritis | Rotavirus
Merck Sharp & Dohme LLC

Completed

Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)

Perennial Allergic Rhinitis
Merck Sharp & Dohme LLC

Terminated

Treatment With Infliximab in a Medical Setting (Study P05587) (OPTIMIST)

Crohn's Disease
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Hepatitis A Virus
Merck Sharp & Dohme LLC

Terminated

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Varicella
Merck Sharp & Dohme LLC

Terminated

Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

Ulcerative Colitis
Merck Sharp & Dohme LLC

Completed

Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Hepatitis B

3

Subscribe